JP2003517011A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517011A5
JP2003517011A5 JP2001544880A JP2001544880A JP2003517011A5 JP 2003517011 A5 JP2003517011 A5 JP 2003517011A5 JP 2001544880 A JP2001544880 A JP 2001544880A JP 2001544880 A JP2001544880 A JP 2001544880A JP 2003517011 A5 JP2003517011 A5 JP 2003517011A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001544880A
Other languages
Japanese (ja)
Other versions
JP2003517011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/033866 external-priority patent/WO2001043742A1/en
Publication of JP2003517011A publication Critical patent/JP2003517011A/ja
Publication of JP2003517011A5 publication Critical patent/JP2003517011A5/ja
Pending legal-status Critical Current

Links

JP2001544880A 1999-12-16 2000-12-14 レフルノミドの新規な製法及び新しい結晶形態 Pending JP2003517011A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17123799P 1999-12-16 1999-12-16
US17122899P 1999-12-16 1999-12-16
US60/171,228 1999-12-16
US60/171,237 1999-12-16
US18264700P 2000-02-15 2000-02-15
US60/182,647 2000-02-15
US20241600P 2000-05-08 2000-05-08
US60/202,416 2000-05-08
PCT/US2000/033866 WO2001043742A1 (en) 1999-12-16 2000-12-14 Novel processes for making- and a new crystalline form of- leflunomide

Publications (2)

Publication Number Publication Date
JP2003517011A JP2003517011A (ja) 2003-05-20
JP2003517011A5 true JP2003517011A5 (https=) 2005-12-22

Family

ID=27496942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001544880A Pending JP2003517011A (ja) 1999-12-16 2000-12-14 レフルノミドの新規な製法及び新しい結晶形態

Country Status (15)

Country Link
US (3) US6610718B2 (https=)
EP (1) EP1242077A4 (https=)
JP (1) JP2003517011A (https=)
KR (1) KR20020067545A (https=)
CN (1) CN1411373A (https=)
AU (1) AU779931B2 (https=)
CA (1) CA2397601A1 (https=)
CZ (1) CZ20022000A3 (https=)
HR (2) HRP20050176A2 (https=)
HU (1) HUP0204069A3 (https=)
IL (1) IL149792A0 (https=)
PL (1) PL356243A1 (https=)
SK (1) SK8332002A3 (https=)
WO (1) WO2001043742A1 (https=)
YU (1) YU45102A (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196764T1 (de) * 1997-08-08 2000-10-15 Aventis Pharma Gmbh Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
WO2001051089A1 (de) * 2000-01-13 2001-07-19 Merck Patent Gmbh Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
CA2400290A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
CN101563082A (zh) * 2006-09-05 2009-10-21 窦德献 治疗免疫介导性皮肤病的组合物和方法
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体(上海)有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
JP2011500780A (ja) 2007-10-24 2011-01-06 ジェネリクス・(ユーケー)・リミテッド 新規結晶形
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・[ユーケー]・リミテッド ボセンタンの製造方法
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
US11801232B2 (en) * 2019-11-27 2023-10-31 Yale University Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE196764T1 (de) * 1997-08-08 2000-10-15 Aventis Pharma Gmbh Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
EP0933633A1 (en) * 1997-12-11 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Process for obtaining L-dihydroorotic acid and use thereof
US7691890B2 (en) * 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CA2377278C (en) * 1999-06-25 2010-03-23 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
CA2400290A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
EP1401801B1 (en) * 2000-08-24 2006-11-02 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2535346A1 (en) * 2003-08-13 2005-03-03 Medtronic, Inc. Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
US20050064005A1 (en) * 2003-08-13 2005-03-24 Dinh Thomas Q. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
WO2005023201A2 (en) * 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis

Similar Documents

Publication Publication Date Title
BE2015C062I2 (https=)
BE2014C035I2 (https=)
JP2001053789A5 (https=)
BE2010C019I2 (https=)
BE2011C032I2 (https=)
BRPI0113420B8 (https=)
BRPI0112928B8 (https=)
BE2011C041I2 (https=)
JP2003517011A5 (https=)
JP2003527977A5 (https=)
JP2003502841A5 (https=)
BRPI0113372A8 (https=)
JP2003508532A5 (https=)
JP2001088289A5 (https=)
JP2000353208A5 (https=)
JP2001222837A5 (https=)
JP2002122199A5 (https=)
HU0004614D0 (https=)
BR122012015772A2 (https=)
CN3147473S (https=)
CN3142478S (https=)
CN3148838S (https=)
CN3147648S (https=)
CN3151857S (https=)
CN3149068S (https=)